Sigma Planning Corp Increases Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

Sigma Planning Corp raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 162.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,231 shares of the biotechnology company’s stock after purchasing an additional 15,012 shares during the quarter. Sigma Planning Corp’s holdings in Sarepta Therapeutics were worth $414,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its holdings in Sarepta Therapeutics by 27.9% in the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock worth $168,907,000 after buying an additional 577,848 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Sarepta Therapeutics by 2.1% during the first quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company’s stock valued at $127,512,000 after purchasing an additional 41,408 shares during the last quarter. EcoR1 Capital LLC boosted its position in shares of Sarepta Therapeutics by 67.8% in the 1st quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company’s stock worth $82,480,000 after purchasing an additional 522,386 shares in the last quarter. Aberdeen Group plc grew its stake in shares of Sarepta Therapeutics by 91.1% in the 2nd quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company’s stock worth $21,500,000 after buying an additional 592,125 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd increased its position in Sarepta Therapeutics by 1,736.5% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 870,181 shares of the biotechnology company’s stock valued at $14,880,000 after buying an additional 822,799 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SRPT. Citigroup started coverage on Sarepta Therapeutics in a research note on Tuesday, July 22nd. They set a “sell” rating for the company. Guggenheim lowered their price target on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday. Mizuho upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $19.00 to $26.00 in a research note on Wednesday. Wells Fargo & Company reduced their price objective on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, Leerink Partnrs downgraded shares of Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 18th. Eight investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Hold” and an average price target of $33.75.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $17.63 on Friday. The firm’s 50-day moving average price is $20.30 and its 200-day moving average price is $25.67. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. The company has a market cap of $1.72 billion, a PE ratio of -20.26 and a beta of 0.52. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company had revenue of $399.36 million for the quarter, compared to analysts’ expectations of $331.51 million. During the same period in the previous year, the firm earned $0.62 earnings per share. The firm’s revenue for the quarter was down 14.5% on a year-over-year basis. As a group, analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.